Show simple item record

ACUTE SEVERE ULCERATIVE COLITIS TREATED WITH ACCELERATED INFLIXIMAB INDUCTION. CASE REPORT

Terapia de inducción acelerada con infliximab en paciente con Colitis Ulcerosa severa refractaria a corticoides. Caso Clínico.

dc.contributoren-US
dc.contributorProyecto Clínica Las Condes N° PIDA2015-003es-ES
dc.creatorFluxá, Daniela; Clínica Las Condes
dc.creatorFlores, Lilian; Clínica Las Condes
dc.creatorKronberg, Udo; Clínica Las Condes
dc.creatorMoreno, Mauricio; Clínica Las Condes
dc.creatorFigueroa, Carolina; Clínica Las Condes
dc.creatorIbáñez, Patricio; Clínica Las Condes
dc.creatorLubascher, Jaime; Clínica Las Condes
dc.creatorSimian, Daniela; Clínica Las Condes
dc.creatorQuera, Rodrigo; Clínica Las Condes
dc.date2017-09-28
dc.date.accessioned2019-11-11T18:28:03Z
dc.date.available2019-11-11T18:28:03Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/5732
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/111404
dc.descriptionAcute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that requires early recognition, hospitalization and adequate treatment. Currently, the use of infliximab in ulcerative colitis (UC) is recommended in the case of severe disease refractory to corticosteroids, once that superimposed bacterial or viral infections (such as cytomegalovirus or Clostridium difficile) have been excluded. However, conventional weight-based regimens of infliximab might be insufficient for patients with ASUC. Accelerated infliximab induction regimen may increase its serum concentration levels and efficacy by reducing early colectomy rates in these patients. We report a 34 year old female presenting with an ASUC. She was initially treated with hydrocortisone 300 mg/day and mesalazine enemas 4g/day with an unfavorable clinical response. At the fifth day of therapy, an accelerated induction therapy with infliximab was started in doses of 10 mg/kg at weeks 0, 1 and 4. After the second dose, there was a favorable response with reduction of abdominal pain, stool frequency and hematochezia. She was discharged with prednisone and azathioprine. After four weeks of starting infliximab, the patient remains in clinical remission.en-US
dc.descriptionAcute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that requires early recognition, hospitalization and adequate treatment. Currently, the use of infliximab in ulcerative colitis (UC) is recommended in the case of severe disease refractory to corticosteroids, once that superimposed bacterial or viral infections (such as cytomegalovirus or Clostridium difficile) have been excluded. However, conventional weight-based regimens of infliximab might be insufficient for patients with ASUC. Accelerated infliximab induction regimen may increase its serum concentration levels and efficacy by reducing early colectomy rates in these patients. We report a 34 year old female presenting with an ASUC. She was initially treated with hydrocortisone 300 mg/day and mesalazine enemas 4g/day with an unfavorable clinical response. At the fifth day of therapy, an accelerated induction therapy with infliximab was started in doses of 10 mg/kg at weeks 0, 1 and 4. After the second dose, there was a favorable response with reduction of abdominal pain, stool frequency and hematochezia. She was discharged with prednisone and azathioprine. After four weeks of starting infliximab, the patient remains in clinical remission.es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/5732/3310
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27798
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27800
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27801
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27802
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27803
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27804
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27805
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27806
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27807
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27808
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/27809
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/28406
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/29643
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/29644
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/29645
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5732/29646
dc.sourceRevista Médica de Chile; Vol. 145, núm. 08 (2017): AGOSTO 2017es-ES
dc.source0034-9887
dc.subjectColitis, Ulcerative; Infliximab; time-To-treatmenten-US
dc.subjectColitis, Ulcerative; Infliximab; time-To-treatmentes-ES
dc.titleACUTE SEVERE ULCERATIVE COLITIS TREATED WITH ACCELERATED INFLIXIMAB INDUCTION. CASE REPORTen-US
dc.titleTerapia de inducción acelerada con infliximab en paciente con Colitis Ulcerosa severa refractaria a corticoides. Caso Clínico.es-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record